Navigation Links
Schering-Plough Reports Financial Results for First Quarter of 2008
Date:4/23/2008

25 26 (3%)

Other Pharmaceuticals 708 390 82%

ANIMAL HEALTH b/ 723 232 211%

CONSUMER HEALTH CARE 377 345 9%

OTC 209 177 18%

OTC CLARITIN 139 127 9%

Foot Care 85 78 9%

Sun Care 83 90 (7%)

CONSOLIDATED GAAP NET SALES $4,657 $2,975 56%

a/ Total Human Prescription Pharmaceuticals net sales for the three months

ended March 31, 2008 include net sales of $861 million from Organon,

the human health segment of Organon BioSciences (OBS), which was

acquired on November 19, 2007.

b/ Total Animal Health net sales for the three months ended March 31, 2008

include net sales of $454 million from Intervet, the animal health

segment of OBS, which was acquired on November 19, 2007.

c/ Products acquired in OBS acquisition on November 19, 2007.

NOTE: Additional information about U.S. and international sales for specific products is available by calling the company or visiting the Investor Relations Web site at http://ir.schering-plough.com.

SCHERING-PLOUGH CORPORATION

Reconciliation of Non-U.S. GAAP Financial Measures

Adjusted net sales, defined as net sales plus an assumed 50 percent of global cholesterol joint venture net sales.

(Dollars in millions) Three months ended March 31

(unaudited)

2008 2007 %

Net sales, as reported a/ $4,657 $2
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
2. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
5. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
6. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
7. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
11. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... 10 Corthera Inc. today,announced that an interim ... portion of a Phase II/III multicenter, randomized, double-blind,international ... the,company,s investigational drug for treatment of acute heart ... presented by John R. Teerlink, M.D.,Professor of Medicine, ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
... today,announced financial results for the second quarter ended September ... quarter, representing an,increase of 27.1% from 100.9 billion yen ... results of PENTAX included in the scope of,consolidation during ... billion yen, a 23.2% decrease compared with,26.8 billion yen ...
Cached Biology Technology:Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 2Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 33SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Hoya Announces Second Quarter and First Half Financial Results for FY2008 2
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
(Date:8/31/2014)... go after each other. But when viruses invade bacteria, ... Sometimes viruses actually carry helpful genes that a bacterium ... attack its own hosts. , Scientists have assumed the ... anything it recognized as invading viral genes. However, new ... variety of the bacterial immune system known as the ...
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
... -- Zeroing in on the early cell mutations that enable a ... a personalized therapy to stop it. Scientists were able to use ... order in which these abnormalities form to analyze the pattern of ... findings, which are published in the July edition of Cancer ...
... 29, 2011 BD Biosciences, a segment of ... availability of BD Recharge™, a chemically defined (CD) ... offers productivity comparable to yeast-based peptones. ... for biopharmaceutical cell culture," said Robert Hallenbeck, Vice ...
... uncovered half-a-billion-year-old fossils demonstrating that primitive animals had excellent vision. ... South Australian Museum and the University of Adelaide ... from a recently swatted fly. This discovery will be ... Nature . The lead author is ...
Cached Biology News:Scientists develop method to determine order of mutations that lead to cancer 2BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2New fossils demonstrate that powerful eyes evolved in a twinkling 2
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... EIA Principle: The ... LTE4 are products of arachidonic ... glutathione-S-transferase. In the past, they ... Substances of Anaphylaxis (SRS-A)". They ...
Biology Products: